Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson’s disease patients

Publication date: Available online 3 September 2019Source: Journal of Clinical NeuroscienceAuthor(s): Li-xia Qin, Jie-qiong Tan, Hai-nan Zhang, Jian-guang Tang, Bo Jiang, Xiang-min Shen, Bei-sha Tang, Chun-yu WangAbstractmicroRNAs have been reported to suppress tumor growth, invasion, and metastasis and play roles in neurodegeneration disorders. Moreover, changes in microRNAs are found in the peripheral blood, cerebrospinal fluid (CSF), and brain tissues in patients of central nervous system diseases, including glioma, Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis and depression. Compared with other bodily fluids, CSF is the most accurate at representing the pathological processes of the brain. To understand whether microRNA expression may be dysregulated in the patients of PD, and to further discover potential diagnostic biomarkers and promising therapeutic targets for PD, we used real-time polymerase chain reaction (RT-PCR) to compare CSF microRNAs from 20 PD patients, 13 AD patients and 27 controls with other neurologic disorders such as encephalitis and Guillain-Barre syndrome. Finally, we found that the mean expression level of hsa-miR-626 was significantly reduced in the CSF of patients with PD compared with AD and controls. Our approach potentially identified a biomarker in CSF that upon further investigation, could be used for the detection, diagnosis, and monitoring of PD in combination with other PD biomarkers.
Source: Journal of Clinical Neuroscience - Category: Neuroscience Source Type: research